A Palpable Mass Cleared by a Dense-Breast Mammogram
Ms. K is 54 and postmenopausal. Five weeks ago she noticed a firm 2 cm lump in the upper outer right breast. A screening mammogram three weeks ago was reported as 'heterogeneously dense, no suspicious finding,' with a recommendation for routine follow-up in 12 months; no additional imaging was ordered. She comes to the breast clinic asking whether she is overreacting. There is no nipple discharge, no skin dimpling, and no family history of breast or ovarian cancer. She takes combined hormone therapy for vasomotor symptoms, started four years ago, and has a BMI of 31. She has no other symptoms and feels well.
1. Is 12-month follow-up appropriate? What is the appropriate next step, and why?
Read the worked answer
No. A persistent, firm, palpable mass is a clinical finding that a negative mammogram does not clear, particularly in heterogeneously dense tissue where mammographic sensitivity falls substantially. The correct next step is a diagnostic, targeted ultrasound of the palpable area, not a repeat screening study in a year.
If ultrasound shows a solid mass, proceed to ultrasound-guided core needle biopsy with clip placement regardless of how benign the sonographic features look. If the ultrasound is negative or shows only a simple cyst but the mass remains clinically suspicious, the discordance itself warrants biopsy, ideally with imaging guidance or surgical consultation. Benign imaging plus a dominant palpable mass is a recognized source of delayed diagnosis.
The hormone therapy is worth addressing separately: use is associated with increased breast density and a modestly increased risk, so the risks and benefits should be revisited with her prescriber if she is otherwise a candidate to stop. Document the clinical finding, the discordance, and the escalation plan at the time of the visit.
2. Core biopsy shows invasive ductal carcinoma, grade 2, 1.4 cm, ER 95%, PR 80%, HER2 IHC 1+ with FISH not amplified, Ki-67 15%. What staging studies are indicated?
Read the worked answer
This is clinical stage I disease, cT1c N0 M0. For early-stage breast cancer with no symptoms and no abnormal laboratory values, ASCO and Choosing Wisely guidance recommends against routine staging with PET/CT, bone scan, or liver imaging. The yield of occult distant disease is low, while the rate of false-positive findings leading to unnecessary biopsy and delay is high.
Reasonable baseline testing is a complete blood count and liver function tests, with alkaline phosphatase if not included, plus pregnancy testing if applicable. Imaging is triggered by symptoms, physical findings, or abnormal labs, not by the diagnosis alone.
HER2 IHC 1+ without amplification is HER2-negative, so no HER2-directed therapy is indicated. That point matters because an IHC 1+ result is sometimes misread as equivocal and leads to a request for repeat testing or trastuzumab, neither of which is appropriate here. Ki-67 at 15% is not a threshold that by itself dictates chemotherapy; recurrence risk should be estimated with a genomic assay or clinical-pathologic tools and discussed with the patient.
3. What is the axillary approach, and how would you counsel her about sentinel node biopsy versus axillary dissection?
Read the worked answer
With a clinically node-negative axilla, the plan is sentinel lymph node biopsy at the time of breast surgery using dual-agent mapping. Axillary lymph node dissection is reserved for a positive sentinel node in situations where the trial-supported de-escalation criteria do not apply, or for clinically node-positive disease. Preoperative axillary ultrasound with fine needle aspiration of suspicious nodes is optional; if it is done and nodes are sonographically normal, proceed directly to sentinel biopsy.
Counseling should be concrete about what each procedure means. Sentinel biopsy alone carries a low lymphedema risk, in the range of about 5 to 7 percent, versus roughly 20 percent after axillary dissection, along with differences in numbness, shoulder mobility, and seroma. She should also hear that if a sentinel node is positive, radiation and systemic therapy decisions largely determine whether further axillary surgery is needed, so the biopsy result is not automatically a ticket to dissection.
Confirm that she understands the sequencing: surgery with sentinel biopsy, then pathology, then a multidisciplinary discussion of radiation and endocrine therapy.